左炔诺孕酮宫内缓释系统暴露时长与乳腺癌发病风险的关联
该回顾性队列研究利用韩国国民健康保险理赔数据库(2013-2022年),纳入2014-2017年间首次诊断为子宫内膜异位症、子宫平滑肌瘤或异常子宫出血的30-49岁女性2,094,029例,经倾向性评分匹配后比较左炔诺孕酮宫内缓释系统(LNG-IUS)使用者与非使用者的乳腺癌发病率。结果显示LNG-IUS使用与乳腺癌风险升高相关(HR 1.38,95%CI 1.192-1.585),且使用初期风险尤其升高,随时间推移有所下降。
要点
- LNG-IUS使用者乳腺癌发病率为223例/10万人年,非使用者为154例/10万人年。
- LNG-IUS使用与乳腺癌风险升高相关(HR 1.38,95%CI 1.192-1.585)。
- 使用初期风险最高(不足3年早期HR 5.40,95%CI 4.037-7.216),随时间下降。
核心结论
- LNG-IUS可能与异常子宫出血、子宫内膜异位症或子宫平滑肌瘤女性的乳腺癌风险升高相关,使用初期风险尤其升高。
研究设计与样本
- 回顾性队列研究,使用韩国国民健康保险理赔数据库(2013-2022年)。
- 纳入2014-2017年间首次诊断为子宫内膜异位症、子宫平滑肌瘤或异常子宫出血的30-49岁女性2,094,029例。
- 采用倾向性评分匹配创建LNG-IUS使用者与非使用者的平衡队列,最终纳入61,010例女性。
- 采用Cox比例风险模型评估LNG-IUS暴露时长与乳腺癌发病率的关联。
主要发现
- LNG-IUS组乳腺癌发病率为223例/10万人年,非LNG-IUS组为154例/10万人年。
- LNG-IUS使用与乳腺癌风险升高相关(HR 1.38,95%CI 1.192-1.585)。
- 使用不足3年:早期HR 5.40(95%CI 4.037-7.216),晚期HR 1.04(95%CI 0.547-1.994)。
- 使用3-4.9年:早期HR 3.44(95%CI 2.671-4.431),晚期HR 1.75(95%CI 1.12-2.723)。
- 使用5年及以上:HR 1.77(95%CI 1.26-2.479)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women. METHODS: A retrospective cohort study was conducted using the Korean National Health Insurance Claims database from 2013 to 2022. A total of 2,094,029 women aged 30-49 years with initial diagnoses of endometriosis, uterine leiomyomas, or abnormal uterine bleeding between 2014 and 2017 were included in the study. Propensity score matching was applied to create balanced cohorts of LNG-IUS users and nonusers. Cox proportional hazards models were used to evaluate the association between LNG-IUS exposure duration and breast cancer incidence. RESULTS: A total of 61,010 women were included in the study cohort. The incidence rate of breast cancer in LNG-IUS group was 223 cases per 100,000 person-years compared with 154 cases per 100,000 person-years in the non-LNG-IUS group. Use of LNG-IUS was linked to an increased breast cancer risk (hazard ratio [HR] 1.38, 95% CI, 1.192-1.585). Analysis of LNG-IUS use over time suggests that early initiation is associated with an increased risk of breast cancer, which may decrease over time (less than 3 years: early HR 5.40, 95% CI, 4.037-7.216; less than 3 years: late HR 1.04, 95% CI, 0.547-1.994; 3-4.9 years: early HR 3.44, 95% CI; 2.671-4.431; 3-4.9 years: late HR 1.75, 95% CI; 1.12-2.723; 5 years or more: HR 1.77, 95% CI, 1.26-2.479). CONCLUSION: The LNG-IUS may be associated with an increased risk of breast cancer among women with abnormal uterine bleeding, endometriosis, or leiomyomas, with the risk being particularly elevated during the initial years of use.
引用
- Yuk JS, Kim MH, Yoon SH, et al. Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence. Obstet Gynecol. 2025. PMID: 40080821. doi:10.1097/AOG.0000000000005881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。